Late-onset Parkinson disease

This phase 3 trial tests whether adding vibostolimab to pembrolizumab (Keytruda) helps people with PD-L1 positive metastatic non-small cell lung cancer live longer than pembrolizumab alone. Over 1,200 participants received either the combination or pembrolizumab every three weeks…

This study tested whether a combination of olaparib (a targeted therapy) and pembrolizumab (an immunotherapy) works better than standard chemotherapy plus pembrolizumab for people with advanced triple-negative breast cancer that initially responded to chemo-immunotherapy. The tri…

This study tested whether adding vibostolimab to the standard immunotherapy pembrolizumab can better prevent melanoma from returning after surgery. About 1,600 people with high-risk stage II to IV melanoma took part. The goal was to see if the combination keeps cancer away longer…

This study tested whether adding two drugs (lenvatinib and pembrolizumab) to a standard liver cancer treatment called TACE helps people with liver cancer that cannot be removed by surgery. About 479 participants received either the drug combo plus TACE or TACE alone. The goal was…

This study tests whether adding lenvatinib to pembrolizumab and chemotherapy helps people with metastatic esophageal cancer live longer. About 864 participants receive either the new three-drug combo or standard care. The goal is to improve overall survival, but this is not a cur…

This study tested a combination of two drugs, favezelimab and pembrolizumab, in 137 people with certain blood cancers like Hodgkin lymphoma and B-cell lymphoma. The goal was to see if the combination was safe and could shrink tumors. The study also looked at each drug alone in so…

This early-stage study tested a new drug called PF-07265807 in people with advanced or metastatic solid tumors that had spread. The main goals were to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to precise, high-dose radiation (SBRT) could help prevent early-stage non-small cell lung cancer from returning. The study enrolled 448 people with stage I or II lung cancer who could not hav…

This early-stage trial tested two drug combinations—TNO155 plus spartalizumab or ribociclib—in 122 adults with advanced solid tumors like lung, head and neck, and colorectal cancers. The goal was to check safety and see if the drugs could slow cancer growth. The study was termina…

This early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with P…